Business

The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge…

Alnylam Pharmaceuticals highlighted the early commercial success of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy during a recent webinar. The company reported a…

AbstractAmyloidosis comprises a heterogeneous group of disorders marked by the extracellular deposition of insoluble protein fibrils, known as amyloids, which can…

License agreement leverages UCB’s expertise in antibody drug discovery to support Refold Therapeutics' ambition of providing better treatments for patients…

TULSA, Okla. -Cardiac amyloidosis, once widely considered a fatal diagnosis, is now being detected earlier and treated with newly approved medications that doctors…

ORLANDO, Fla. - Cardiac amyloidosis is a systemic disorder that affects the heart and can also affect other organs such as the kidneys and nervous system.…

We are raising funds in loving memory of our mum, who sadly passed away from cardiac amyloidosis on 10/12/2025.Amyloidosis is a rare and often misunderstood…

Amyloidosis is a rare, chronic condition in which abnormal proteins bunch together to form amyloid deposits. These deposits can build in certain body organs such as…

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end…

A new Mayo Clinic study questions the benefit of implantable cardioverter-defibrillator use to treat patients with transthyretin cardiac amyloidosis.For patients…